TITLE

PROTALIX GETS FDA FAST TRACK DESIGNATION FOR PRGCD

PUB. DATE
October 2009
SOURCE
Worldwide Biotech;Oct2009, Vol. 21 Issue 10, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article announces that Protalix BioTherapeutics, Inc. has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for glucocerebrosidase (prGCD) for the treatment of Gaucher disease. Fast Track designation is said to be an FDA approved process that provides faster and easier review of drugs in treating serious diseases. It states that instead of filling all the sections of the New Drug Application (NDA) at once, a company files the sections as they become available.
ACCESSION #
44276417

 

Related Articles

  • FDA Query Gives Confidence to Protalix for Gaucher Drug. Osborne, Randy // BioWorld Today;7/7/2009, Vol. 20 Issue 128, p1 

    The article speculates the possibility of a U.S. Food and Drug Administration approval for Protalix BioTherapeutics Incorporated's prGCD drug in 2009. The drug, considered as would-be Cerezyme competitor, is Protalix's therapy for the enzyme-replacement therapy for Gaucher disease. Information...

  • FDA Gives Nod to Protalix's Elelyso in Gaucher Disease. Powers, Marie // BioWorld Today;5/3/2012, Vol. 23 Issue 86, p1 

    The article reports on the approval given by the U.S. Food and Drug Administration (FDA) to Elelyso, a recombinant version of the hydrolytic human lysosomal enzyme glucocerebrosidase, for Gaucher disease. The approval allows Elelyso to become the first plant cell-based enzyme replacement therapy...

  • Protalix's Gaucher Drug May Fill Gap Left from Genzyme Plant Closure.  // BioPharm International;Aug2009, Vol. 22 Issue 8, p15 

    The article reports that the Food and Drug Administration (FDA) is asking Protalix BioTherapeutics to consider submitting a treatment protocol for the use of prGC, the company's development drug for patients with Gaucher disease. It states that the FDA believes the company's development program...

  • OTHER NEWS TO NOTE.  // BioWorld Today;8/18/2009, Vol. 20 Issue 158, p2 

    This section offers world news briefs related to the biotechnology industry. According to Crucell NV in Leiden, the Netherlands, a supranational organization has awarded the first portion of contracts for supplies of its Quinvaxem pediatric vaccine. The U.S. Food and Drug Administration (FDA)...

  • Protalix Cleared for Phase 1/2 Trial of PRX-102.  // Drug Discovery & Development;Sep/Oct2012, Vol. 15 Issue 8, p28 

    The article reports on the clearance received by Protalix BioTherapeutics Inc. from the U.S. Food and Drug Administration (FDA) on its Investigational New Drug (IND) application to initiate Phase 1/2 clinical trials of PRX-102 recombinant alpha-galactosidase-A for the treatment of Fabry disease.

  • CRL for Gaucher's Drug; More Expenses Ahead for Protalix.  // Bioworld Week;3/7/2011, Vol. 19 Issue 10, p2 

    The article reports on the approval of the drug, a lead compound taliglucerase alfa for Gaucher's disease wherein the drugmaker Protalix BioTherapeutics Inc. has been working on the complete response letter (CRL) from the U.S. Food and Drug Administration. It was in November 2009 that Pfizer and...

  • Decisions Update.  // PharmaWatch: Biotechnology;Sep2007, Vol. 6 Issue 9, p13 

    The article offers regulatory news updates in the international biotechnology industry. Protalix BioTherapeutics Inc. has received approval on the final design of its pivotal phase III clinical trial for its lead product candidate prGCD. Canadian biotech QLT Inc. said that the U.S. Food and Drug...

  • Pharmers Plow Their Way Towards Protein Success. Agres, Ted // Drug Discovery & Development;Jul/Aug2012, Vol. 15 Issue 7, p6 

    The article reports on the increased number of plant-based biologic drugs in 2012 in the U.S. It mentions the Food and Drug Administration (FDA) approval of Protalix BioTherapeutics Inc.'s Elelyso which is an injectable enzyme for treatment of Type 1 Gaucher disease. It also cites Biolex...

  • Protalix: $115M Gaucher's Deal with Pfizer is Just the Beginning. Morrison, Trista // BioWorld International;12/9/2009, Vol. 14 Issue 49, p5 

    The article reports on the 115-million U.S. dollar profit-sharing deal between Protalix BioTherapeutics Inc. and Pfizer Inc. for the development of Upsylo, a drug for Gaucher's disease. Milestone payments are expected to be given soon to the former as the drug application has a fast-track status...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics